BASEL, Switzerland,
May 18, 2017 /PRNewswire/ -- Myovant
Sciences (NYSE: MYOV), a leading clinical-stage
biopharmaceutical company focused on women's health and endocrine
diseases, today announced the presentation of data from a Phase 2
trial of relugolix in women with endometriosis-associated pain at
two upcoming medical meetings. Twelve-week findings from the trial
will be presented during an oral presentation at the
13th World Congress on Endometriosis (WCE), which is
being held May 17-20 in Vancouver, Canada. Twenty-four-week data from
an extension of the same trial will be presented during a poster
session at the 19th European Congress of Endocrinology
(ECE), which is being held May 20-23
in Lisbon, Portugal. Details of
the presentations are below.
WCE Oral Presentation Details:
- Date and Time: May 19,
2017 from 1:35 to 1:50 p.m.
PT
- Abstract (#MS08-02): Results from a Phase 2 Study of
Relugolix, an Oral Gonadotropin-Releasing Hormone Receptor
Antagonist, vs. Placebo in Women with Endometriosis-Associated
Pain
- Location: Vancouver,
Canada
- Presenter: Dr. Yutaka Osuga, The University of Tokyo
ECE Poster Presentation Details:
- Date and Time: May 23,
2017 from 12:45 to 1:45 p.m.
UTC
- Abstract (#GP134): Relugolix, an Oral
Gonadotropin‐Releasing Hormone Receptor Antagonist, in Women with
Endometriosis‐Associated Pain: Phase 2 Safety and Efficacy 24‐Week
Results
- Location: Lisbon,
Portugal
- Presenter: Dr. Yutaka Osuga, The University of Tokyo
About Endometriosis
Endometriosis is a disease in which tissue that normally lines
the uterus is found outside the uterine cavity, commonly in the
lower abdomen or pelvis, on ovaries, the bladder, and the colon.
This tissue outside the uterus results in chronic inflammation and
can cause scarring and adhesions. The symptoms associated with
endometriosis include painful periods and chronic pelvic pain,
painful ovulation, pain during or after sexual intercourse, heavy
bleeding, fatigue, and infertility. Endometriosis can also impact
general physical, mental, and social well-being. For
endometriosis-associated pain, initial treatment options include
oral contraceptives and over-the-counter pain medications. In more
severe cases, GnRH agonists such as leuprorelin are used for
short-term treatment. It is estimated that approximately 6 million
women in the United States suffer
from symptomatic endometriosis, 1.2 million of whom are
inadequately treated by oral contraceptives and require additional
treatment.
About Myovant Sciences
Myovant Sciences is a clinical-stage biopharmaceutical company
focused on developing and commercializing innovative therapies for
women's health and endocrine diseases. Myovant's lead product
candidate is relugolix, an oral, once-daily small molecule GnRH
receptor antagonist. Myovant has initiated a Phase 3 clinical
program, consisting of two international clinical trials, LIBERTY 1
and LIBERTY 2, for relugolix in women with heavy menstrual bleeding
associated with uterine fibroids, as well as a Phase 3 clinical
trial, HERO, for relugolix in men with advanced prostate cancer.
Myovant plans to initiate an additional Phase 3 clinical program
for relugolix in women with endometriosis-associated pain in the
second quarter of 2017. Myovant is simultaneously developing
MVT-602, an analog of kisspeptin, for the treatment of female
infertility as part of assisted reproduction. Over time the company
intends to expand its development pipeline to include other
potential treatments for women's health and endocrine-related
diseases. For more information, please visit the company's website
at myovant.com.
Media Contact:
Julie Normart
Pure Communications
jnormart@purecommunications.com
415.946.1087
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/myovant-sciences-announces-upcoming-presentations-of-relugolix-data-from-phase-2-trial-in-women-with-endometriosis-associated-pain-300459771.html
SOURCE Myovant Sciences